<table id="table_4" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 4. Effects of Trilipix or Fenofibrate Co-Administration on Systemic Exposure of Other Drugs</caption>
<colgroup>
<col width="30%"></col>
<col width="30%"></col>
<col width="20%"></col>
<col width="10%"></col>
<col width="10%"></col>
</colgroup>
<tbody>
<tr>
<td stylecode="Toprule">Dosage Regimen of<br/> Trilipix or Fenofibrate</td>
<td stylecode="Toprule">Dosage Regimen of<br/> Co-Administered Drug</td>
<td colspan="3" stylecode="Toprule" valign="top">Change in Co-Administered Drug Exposure</td>
</tr>
<tr>
<td align="left" stylecode="Botrule"> </td>
<td stylecode="Botrule"> </td>
<td stylecode="Botrule">Analyte</td>
<td stylecode="Botrule">AUC</td>
<td stylecode="Botrule">C<sub>max</sub>
</td>
</tr>
<tr>
<td align="left" colspan="5">
<content stylecode="italics">Lipid-lowering agents</content>
</td>
</tr>
<tr>
<td>Trilipix 135 mg QD for 10 days</td>
<td>Rosuvastatin, 40 mg QD for 10 days</td>
<td>Rosuvastatin</td>
<td>↑6%</td>
<td>↑20%</td>
</tr>
<tr>
<td>Fenofibrate 160 mg<sup>1</sup> QD for 10 days</td>
<td>Atorvastatin, 20 mg QD for 10 days</td>
<td>Atorvastatin</td>
<td>↓17%</td>
<td>0%</td>
</tr>
<tr>
<td>Fenofibrate 3 x 67 mg<sup>2</sup> as a single dose</td>
<td>Pravastatin, 40 mg as a single dose</td>
<td>Pravastatin</td>
<td>↑13%</td>
<td>↑13%</td>
</tr>
<tr>
<td align="left"> </td>
<td align="left"> </td>
<td>3α-Hydroxyl-iso-pravastatin</td>
<td>↑26%</td>
<td>↑29%</td>
</tr>
<tr>
<td>Fenofibrate 160 mg<sup>1</sup> as a single dose</td>
<td>Fluvastatin, 40 mg as a single dose</td>
<td>(+)-3R, 5S-Fluvastatin</td>
<td>↑15%</td>
<td>↑16%</td>
</tr>
<tr>
<td>Fenofibrate 160 mg<sup>1</sup> QD for 7 days</td>
<td>Simvastatin, 80 mg QD for 7 days</td>
<td>Simvastatin acid</td>
<td>↓36%</td>
<td>↓11%</td>
</tr>
<tr>
<td align="left"> </td>
<td align="left"> </td>
<td>Simvastatin</td>
<td>↓11%</td>
<td>↓17%</td>
</tr>
<tr>
<td align="left"> </td>
<td align="left"> </td>
<td>Active HMG-CoA Inhibitors</td>
<td>↓12%</td>
<td>↓1%</td>
</tr>
<tr>
<td align="left"> </td>
<td align="left"> </td>
<td>Total HMG-CoA Inhibitors</td>
<td>↓8%</td>
<td>↓10%</td>
</tr>
<tr>
<td align="left" colspan="4">
<content stylecode="italics">Anti-diabetic agents</content>
</td>
<td> </td>
</tr>
<tr>
<td>Fenofibrate 145 mg<sup>1</sup> QD for 10 days</td>
<td>Glimepiride, 1 mg as a single dose</td>
<td>Glimepiride</td>
<td>↑35%</td>
<td>↑18%</td>
</tr>
<tr>
<td>Fenofibrate 54 mg<sup>1</sup> TID for 10 days</td>
<td>Metformin, 850 mg TID for 10 days</td>
<td>Metformin</td>
<td>↑3%</td>
<td>↑6%</td>
</tr>
<tr>
<td>Fenofibrate 145 mg<sup>1</sup> QD for 14 days</td>
<td>Rosiglitazone, 8 mg QD for 5 days</td>
<td>Rosiglitazone</td>
<td>↑6%</td>
<td>↓1%</td>
</tr>
<tr>
<td align="left" colspan="5" stylecode="Botrule">
<sup>1 </sup> TriCor (fenofibrate) oral tablet<br/>
<sup>2</sup> TriCor (fenofibrate) oral micronized capsule</td>
</tr>
</tbody>
</table>